SCHEMBL9609625

SCHEMBL9609625

Cc1cccc(C(=O)Nc2ccc(C)c(I)c2)c1

nearest known ligand 0.69

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KCNK3 O14649 10/20 0.69
KCNK9 Q9NPC2 8/20 0.69
KCNH2 Q12809 1/20 0.69
KMT2A Q03164 6/20 0.65
MEN1 O00255 5/20 0.65
RXFP1 Q9HBX9 1/20 0.65
NPC1 O15118 2/20 0.64
RAB9A P51151 2/20 0.64
TP53 P04637 2/20 0.64
POLB P06746 1/20 0.64
KDM4E B2RXH2 1/20 0.64
MAPT P10636 1/20 0.64
L3MBTL1 Q9Y468 1/20 0.63
NT5E P21589 1/20 0.58
BRAF P15056 1/20 0.57
FFAR1 O14842 1/20 0.57
GLA P06280 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15045382 0.88 KCNK3 (0.69) KCNK3KCNK9KCNH2KMT2AMEN1
SCHEMBL18775273 0.88 MEN1 (0.69) KCNK3KCNK9KCNH2KMT2AMEN1
SCHEMBL29744477 0.86 KMT2A (0.69) KCNK3KCNK9KMT2AMEN1NPC1
SCHEMBL15006333 0.86 KCNK3 (0.76) KCNK3KCNK9KCNH2KMT2AMEN1
SCHEMBL13197997 0.86 KMT2A (0.69) KCNK3KCNK9KMT2AMEN1NPC1
SCHEMBL2887294 0.83 MAPK14 (0.69) KCNK3RAB9ATP53KDM4EMAPT
SCHEMBL30798907 0.83 TP53 (0.74) KCNK3KCNK9KCNH2KMT2AMEN1
SCHEMBL27383417 0.83 TP53 (0.74) KCNK3KCNK9KCNH2KMT2AMEN1
SCHEMBL4253897 0.82 KCNK3 (0.93) KCNK3KCNK9KCNH2KMT2AMEN1
SCHEMBL2883773 0.82 MEN1 (0.68) KCNK3KCNK9KMT2AMEN1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170349588-A1 1H-1,8-NAPHTHYRIDIN-2-ONES AS ANTI PROLIFERATIVE COMPOUNDS NATCO PHARMA LIMITED (IN) 2017-12-07 US disclosed
US-9765072-B2 1H-1,8-naphthyridin-2ones as anti proliferative compounds NATCO PHARMA LIMITED (US) 2017-09-19 US disclosed
US-20170114057-A1 1H-1,8-NAPHTHYRIDIN-2ONES AS ANTI PROLIFERATIVE COMPOUNDS NATCO PHARMA LIMITED (IN) 2017-04-27 US disclosed
US-20160368917-A1 Bicyclic Heteroaryl Compounds ARIAD PHARMA INC (US) 2016-12-22 US disclosed
US-9522910-B2 Protein kinase inhibitors (variants), use thereof in treating oncological diseases and a pharmaceutical composition based thereon Obshchestvo s ogranichennoy otvetstvennostyou “Fusion Pharma” (RU) 2016-12-20 US disclosed
US-9278971-B2 Substituted acetylenic pyrazolo[1,5-a]pyrimidines as kinase inhibitors ARIAD PHARMACEUTICALS, INC. (US) 2016-03-08 US disclosed
US-9090561-B2 Acetylenic heteroaryl compounds ARIAD PHARMACEUTICALS, INC. (US) 2015-07-28 US disclosed
US-9029533-B2 Substituted acetylenic imidazo[1,2-A]pyridazines as kinase inhibitors ARIAD PHARMACEUTICALS, INC. (US) 2015-05-12 US disclosed
US-20140288082-A1 Bicyclic Heteroaryl Compounds TAKEDA PHARMACEUTICALS U.S.A., INC. 2014-09-25 US disclosed
US-20140213592-A1 Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon OBSHCHESTVO S OGRANICHENNOY OTVETSTVENNOSTYOU "FUSION PHARMA" (RU) 2014-07-31 US disclosed
US-20140066434-A1 Methods and Compositions for Treating Parkinson's Disease ARIAD PHARMACEUTICALS, INC. (US) 2014-03-06 US disclosed
US-20140045826-A1 METHODS AND COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES ARIAD PHARMACEUTICALS, INC. (US) 2014-02-13 US disclosed
US-8586566-B2 Unsaturated heterocyclic derivatives ARIAD PHARMACEUTICALS, INC. (US) 2013-11-19 US disclosed
US-20130231337-A1 Bicyclic Heteroaryl Compounds ARIAD PHARMACEUTICALS, INC. (US) 2013-09-05 US disclosed
US-20130196979-A1 Bicyclic Heteroaryl Compounds ARIAD PHARMACEUTICALS, INC. (US) 2013-08-01 US disclosed
US-8470851-B2 Substituted acetylenic imidazo[1,2-A]pyridine compounds as kinase inhibitors ARIAD PHARMACEUTICALS, INC. (US) 2013-06-25 US disclosed
US-20130018046-A1 Acetylenic Heteroaryl Compounds ARIAD PHARMACEUTICALS, INC. (US) 2013-01-17 US disclosed
US-20130005738-A1 Monocyclic Heteroaryl Compounds ARIAD PHARMACEUTICALS, INC. (US) 2013-01-03 US disclosed
US-20120178716-A1 Unsaturated Heterocyclic Derivatives ARIAD PHARMACEUTICALS, INC. (US) 2012-07-12 US disclosed
US-20120135986-A1 Bicyclic Heteroaryl Compounds ARIAD PHARMACEUTICALS, INC. (US) 2012-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170349588-A1 1H-1,8-NAPHTHYRIDIN-2-ONES AS ANTI PROLIFERATIVE COMPOUNDS ABL1, MKI67, MCL1 KCNK3 2663/4885KCNK9 2420/4885KCNH2 2832/4885
US-20130005738-A1 Monocyclic Heteroaryl Compounds CYP3A43, CYP2F1, CYP11B2 KCNK3 1849/4885KCNK9 2766/4885KCNH2 1623/4885
US-20140066434-A1 Methods and Compositions for Treating Parkinson's Disease PARK7, SNCA, HTT KCNK3 846/4885KCNK9 1099/4885KCNH2 512/4885
US-20160368917-A1 Bicyclic Heteroaryl Compounds CYP3A43, CYP11B2, CYP2F1 KCNK3 1755/4885KCNK9 2765/4885KCNH2 1587/4885
US-20130196979-A1 Bicyclic Heteroaryl Compounds CYP3A43, CYP11B2, CYP2F1 KCNK3 1755/4885KCNK9 2765/4885KCNH2 1587/4885
US-20130018046-A1 Acetylenic Heteroaryl Compounds NAT1, AADAC, ACACA KCNK3 2924/4885KCNK9 2602/4885KCNH2 2769/4885
US-20120178716-A1 Unsaturated Heterocyclic Derivatives CYP2F1, CYP2J2, ALOX5 KCNK3 3185/4885KCNK9 3612/4885KCNH2 2706/4885
US-20140045826-A1 METHODS AND COMPOSITIONS FOR TREATING NEURODEGENERATIVE DISEASES HTT, MAPT, SNCA KCNK3 1230/4885KCNK9 1252/4885KCNH2 1159/4885
US-20140288082-A1 Bicyclic Heteroaryl Compounds CYP3A43, CYP11B2, CYP2F1 KCNK3 1755/4885KCNK9 2765/4885KCNH2 1587/4885
US-20130231337-A1 Bicyclic Heteroaryl Compounds CYP3A43, CYP11B2, CYP2F1 KCNK3 1755/4885KCNK9 2765/4885KCNH2 1587/4885
US-20120135986-A1 Bicyclic Heteroaryl Compounds CYP3A43, CYP11B2, CYP2F1 KCNK3 1755/4885KCNK9 2765/4885KCNH2 1587/4885
US-20140213592-A1 Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon ABL1, ABL2, MAP3K6 KCNK3 952/4885KCNK9 1136/4885KCNH2 3467/4885
US-20170114057-A1 1H-1,8-NAPHTHYRIDIN-2ONES AS ANTI PROLIFERATIVE COMPOUNDS ABL1, MKI67, ABL2 KCNK3 2206/4885KCNK9 2222/4885KCNH2 2676/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.